Cas:457097-75-5 1-Methyl-3-pyrrolidinamine manufacturer & supplier

We serve Chemical Name:1-Methyl-3-pyrrolidinamine CAS:457097-75-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

1-Methyl-3-pyrrolidinamine

Chemical Name:1-Methyl-3-pyrrolidinamine
CAS.NO:457097-75-5
Synonyms:3-Pyrrolidinamine, 1-methyl-;3-Pyrrolidinamine, 1-methyl-, (3R)-;1-Methylpyrrolidin-3-amine;(R)-1-Methylpyrrolidin-3-amine;(R)-1-METHYL-PYRROLIDIN-3-YLAMINE;(3R)-1-Methyl-3-pyrrolidinamine;1-Methyl-3-pyrrolidinamine;1-Methyl-pyrrolidin-3-ylamine
Molecular Formula:C5H12N2
Molecular Weight:100.162
HS Code:2933990090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:109.6±8.0 °C at 760 mmHg
Density:0.9±0.1 g/cm3
Index of Refraction:1.476
PSA:29.26000
Exact Mass:100.100044
LogP:-0.46

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 3-Pyrrolidinamine, 1-methyl- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-Methyl-pyrrolidin-3-ylamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-Methyl-3-pyrrolidinamine Use and application,1-Methyl-pyrrolidin-3-ylamine technical grade,usp/ep/jp grade.


Related News: The monthly injection to suppress the virus that causes AIDS was aimed as an alternative to daily pills. 1-Methyl-3-pyrrolidinamine manufacturer According to the business type, it can be divided into non-CMO business of APIs and intermediates and CMO business of APIs and intermediates. 1-Methyl-3-pyrrolidinamine supplier Targets within the tumor microenvironment may include both plasma membrane proteins as well as proteins typically secreted into the extracellular space. 1-Methyl-3-pyrrolidinamine vendor Darzalex does have another regimen approved for the same myeloma population. Darzalex combined with Takeda’s Velcade, melphalan and prednisone (VMP) reduced the risk of death by 40% in the phase 3 ALCYONE trial. But disease progression had already occurred in half of patients on the Darzalex-VMP combo after about three years of follow-up, a much shorter period than the five-year mark the Darzalex-Rd regimen is approaching. 1-Methyl-3-pyrrolidinamine factory According to the business type, it can be divided into non-CMO business of APIs and intermediates and CMO business of APIs and intermediates.